Clinical Trials Browser

Active not recruiting × INDUSTRY × Drug Therapy × Clear all

Select Advanced Solid Tumors

NCT04868877 2026-02-19

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT03661320 2026-02-03

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Phase 3 Active not recruiting

855 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT03570892 2026-01-06

BELINDA

Phase 3 Active not recruiting

331 enrolled 10 charts

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05111626 2025-12-15

FORTITUDE-102

Phase 3 Active not recruiting

515 enrolled

Gastrointestinal

Stomach Neoplasms

NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Phase 1 Active not recruiting

610 enrolled

Other solid neoplasmSarcoma

Advanced Solid Tumors

NCT05468489 2025-10-21

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Phase 3 Active not recruiting

200 enrolled

Thoracic

Extensive Stage Small Cell Lung Cancer

NCT04888312 2025-10-08

OPTIMIZE-1

Phase 1/2 Active not recruiting

94 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT07145333 2025-09-08

Drug-SNP

Phase 2/3 Active not recruiting

600 enrolled

Thoracic

SCLC

NCT01064466 2025-07-24

Drugs-SNPs

Phase 2/3 Active not recruiting

600 enrolled

Thoracic

Neoplasms, Small Cell Lung Carcinoma

NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Phase 1 Active not recruiting

39 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT03710876 2025-05-20

INFINITE

Phase 3 Active not recruiting

53 enrolled 23 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT03949283 2024-08-22

Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer

Phase 3 Active not recruiting

150 enrolled

Gynecologic

Ovarian Neoplasms

Clinical Trials

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

BELINDA

FORTITUDE-102

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

OPTIMIZE-1

Drug-SNP

Drugs-SNPs

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

INFINITE

Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer